Sorawee Yanwinitchai

Ms. Sorawee Yanwinitchai

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
SYSorawee Yanwinitchai
Sorawee Yanwinitchai
HDHuy M. Dao
Huy M. Dao
CMChaeho Moon
Chaeho Moon
Robert Williams IIIRobert Williams III
Robert Williams III

18 August 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MSMichael A. Sandoval
Michael A. Sandoval
QLQin Li
Qin Li
RSRuiqi Shi
Ruiqi Shi
BGBhupendra R. Giri
Bhupendra R. Giri
SYSorawee Yanwinitchai
Sorawee Yanwinitchai
ZCZhengrong Cui
Zhengrong Cui

15 July 2026 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
SYSorawee Yanwinitchai
Sorawee Yanwinitchai
CMChaeho Moon
Chaeho Moon
BBBeatriz Behrend-Keim
Beatriz Behrend-Keim
DIDonald E. Owens Iii
Donald E. Owens Iii
JKJohn J. Koleng
John J. Koleng
Robert Williams IIIRobert Williams III
Robert Williams III

19 September 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
CMChaeho Moon
Chaeho Moon
EMEsther Y. Maier
Esther Y. Maier
ESErin H. Seeley
Erin H. Seeley
ZWZachary Warnken
Zachary Warnken
BBBeatriz Behrend-Keim
Beatriz Behrend-Keim
Robert Williams IIIRobert Williams III
Robert Williams III

Verified
Journal Article
Open access
PDF file
Alexandra Manuela Lemos OliveiraAlexandra Manuela Lemos Oliveira
Alexandra Manuela Lemos Oliveira
Maria RaposoMaria Raposo
Maria Raposo
SYSorawee Yanwinitchai
Sorawee Yanwinitchai
Robert Williams IIIRobert Williams III
Robert Williams III
NJNykola C. Jones
Nykola C. Jones
GSGabriela Silva
Gabriela Silva
Glaucoma drainage device (GDD) surgery is frequently limited by postoperative fibroblast proliferation, leading to device failure and the need for revision procedures. In this work, we developed a spray-assisted layer-by-layer (LbL) drug delivery system for GDD surfaces intended to enable localized release of antiproliferative agents, as a proof-of-concept approach toward more standardized patient care. Multilayer thin films composed of poly(β-amino ester) (PBAE) and a 5-fluorouracil (5-FU) and β-cyclodextrin (β-CD) complex (5-FU:β-CD) were fabricated, without (type A films) and with (type B films) graphene oxide (GO) barrier layers. Film growth was monitored by ultraviolet–visible spectroscopy (UV-Vis) and vacuum ultraviolet spectroscopy (VUV), confirming consistent, sequential deposition; type A films exhibited lower variability than GO-containing type B films. Drug release studies revealed a rapid burst release within the first 5 min, followed by a plateau, regardless of GO incorporation, indicating that sustained drug release was not achieved under the current film architecture. Cell cycle analysis confirmed that β-CD complexation preserved the biological activity of 5-FU, which induced an S-phase arrest in a dose-dependent manner. Although further optimization of film architecture and composition is required to improve release control and achieve sustained delivery, this study demonstrates the feasibility of spray-assisted LbL coatings as a localized drug delivery strategy for GDD surfaces. Overall, these findings support the proof-of-concept nature of this approach and identify key parameters that must be optimized before translational applicability can be established.

14 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Alexandra Manuela Lemos OliveiraAlexandra Manuela Lemos Oliveira
Alexandra Manuela Lemos Oliveira
Maria RaposoMaria Raposo
Maria Raposo
SYSorawee Yanwinitchai
Sorawee Yanwinitchai
Robert Williams IIIRobert Williams III
Robert Williams III
NJNykola C. Jones
Nykola C. Jones
GSGabriela Silva
Gabriela Silva
Glaucoma drainage device (GDD) surgery is frequently limited by postoperative fibro-blast proliferation, leading to device failure and the need for revision procedures. In this work, we developed a spray-assisted layer-by-layer (LbL) drug delivery system for GDD surfaces that enables localized release of antiproliferative agents, aiming to standardize patient care. Multilayer thin films composed of poly(β-amino ester) (PBAE) and a 5-fluorouracil (5-FU) and β-cyclodextrin (β-CD) complex (5-FU:β-CD) were fabricated, without (type A films) and with (type B films) graphene oxide (GO) barrier layers. Film growth was monitored by ultraviolet–visible spectroscopy (UV-Vis) and vacuum ultraviolet spectroscopy (VUV), confirming consistent, sequential deposition; type A films exhibited greater reproducibility than GO-containing type B films. Drug release studies revealed a rapid burst release within the first 5 min, fol-lowed by a plateau, regardless of GO incorporation. Cell cycle analysis confirmed that β-CD complexation preserved the biological activity of 5-FU, which induced an S-phase arrest in a dose-dependent manner. Although further optimization of film archi-tecture and composition is required to achieve sustained release, this study demon-strates the feasibility of spray-assisted LbL coatings as a localized drug delivery strate-gy for GDD surfaces. Overall, these findings establish a promising platform for the fu-ture development of more effective and standardized coatings for glaucoma surgical devices.